Table 2.
Examples of clinical trials evaluating efficacy of RT+ICI combinations.
| Indication | Phase | Clinical outcomes | Reference | |
|---|---|---|---|---|
| Melanoma brain metastases | II | SRS and Ipilimumab (n = 45) |
6-month intracranial PFS 48% 12-month intracranial PFS 17% 12-month extracranial PFS 17% OS 68% |
(4) |
| SRS and Nivolumab (n = 35) |
6-month intracranial PFS 69% 12-month intracranial PFS 42% 12-month extracranial PFS 37% OS 78% |
|||
| Diffuse intrinsic pontine glioma | R | reRT and Nivolumab (n=8) |
OS 22.9 months (p<0.0001) |
(115) |
| reRT alone (n=4) | OS 20.4 months (p<0.0001) |
|||
| No reRT or ICI (n=19) | OS 8.3 months (p<0.0001) |
|||
| Advanced solid tumors | I | SBRT and Pembrolizumab (n=79) | OR 13.2% OS 9.6 months PFS 3.1 months |
(116) |
| Metastatic non-small cell lung cancer | III | (117) | ||
| CT and RT and Durvalumab (n = 473) |
PFS 16.8 months | |||
| Advanced melanoma | III | Ipilimumab and RT (n=70) |
OS 19 months (p=0.01) PFS 5 months (p=0.20) CR 25.7% (p=0.04) OR 37.1% (p=0.11) |
(118) |
| Ipilimumab alone (n=31) |
OS 10 months (p=0.01) PFS 3 months (p=0.20) CR 6.5% (p=0.04) OR 19.4% (p=0.11) |
|||
SRS, stereotactic radiosurgery; SBRT, stereotactic body RT; OS, overall survival; PFS, progression free survival; CR, complete response; OR, overall response; R, retrospective trial.